Ajanta Pharma Limited
NSE: AJANTPHARM BSE: AJANTPHARM
NSE
2,555.10
-24.00 (-0.93%)
Prev Close
2579.1
Open Price
2592
Volume
14,543
Today Low / High
2550 / 2592.1
52 WK Low / High
2327.3 / 3428
Range
2,427 - 2,683
BSE
2,553.00
-25.55 (-0.99%)
Prev Close
2578.55
Open Price
2570
Volume
621
Today Low / High
2550.6 / 2571.75
52 WK Low / High
2022.05 / 3464
Range
2,425 - 2,681
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2555.1 (target range: 2,427 - 2,683), reflecting a change of -24 (-0.93056%). On the BSE, it is listed at 2553 (target range: 2,425 - 2,681), showing a change of -25.55 (-0.99087%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
12 Sep
2,574.00
0.20%
11 Sep
2,600.10
-1.08%
10 Sep
2,585.30
0.33%
09 Sep
2,575.00
-0.53%
08 Sep
2,615.70
-0.96%
05 Sep
2,575.20
1.51%
04 Sep
2,562.00
1.51%
03 Sep
2,492.70
2.60%
02 Sep
2,452.10
1.14%
01 Sep
2,505.00
-2.12%
29 Aug
2,508.30
-1.22%
28 Aug
2,579.10
-2.75%
26 Aug
2,616.10
-1.41%
25 Aug
2,639.80
-0.67%
22 Aug
2,650.20
-0.44%
21 Aug
2,655.10
0.05%
Ajanta Pharma Limited Graph
Ajanta Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ajanta Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,555.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,553.00 | 2,578.53 | 2,320.68 - 2,836.38 |
| 2,604.06 | 2,083.25 - 3,124.87 | ||
| 2,629.59 | 1,840.71 - 3,418.47 | ||
| Bearish Scenario | 2,553.00 | 2,527.47 | 2,274.72 - 2,780.22 |
| 2,501.94 | 2,001.55 - 3,002.33 | ||
| 2,476.41 | 1,733.49 - 3,219.33 |
Overview of Ajanta Pharma Limited
ISIN
INE031B01049
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
133,680
Market Cap
322,222,437,600
Last Dividend
54
Official Website
IPO Date
2002-07-01
DCF Diff
-5,160.49
DCF
7,856
Financial Ratios Every Investor Needs
Stock Dividend of AJANTPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-11-06 | November 06, 24 | 28 | 28 | 2024-11-06 | 2024-11-27 | |
| 2024-02-08 | February 08, 24 | 26 | 26 | 2024-02-08 | 2024-03-01 | |
| 2023-08-04 | August 04, 23 | 10 | 10 | 2023-08-04 | 2023-08-26 | |
| 2022-11-11 | November 11, 22 | 7 | 7 | 2022-11-14 | 2022-12-03 | |
| 2021-11-09 | November 09, 21 | 6.33333 | 9.5 | 2021-11-10 | 2021-11-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,648.10 Cr | 1,070.76 Cr | 3,577.34 Cr | 0.7696 | 224.00 Cr | 157.12 Cr | 2,263.65 Cr | 920.39 Cr | 73.56 | 1,268.32 Cr | 0.1980 |
| 2024-03-31 | 4,208.71 Cr | 1,115.32 Cr | 3,093.39 Cr | 0.7350 | 207.73 Cr | 129.54 Cr | 1,967.73 Cr | 816.17 Cr | 64.82 | 1,256.54 Cr | 0.1939 |
| 2023-03-31 | 3,742.64 Cr | 1,050.40 Cr | 2,692.24 Cr | 0.7193 | 237.01 Cr | 71.07 Cr | 711.07 Cr | 587.98 Cr | 45.89 | 881.40 Cr | 0.1571 |
| 2022-03-31 | 3,284.13 Cr | 886.72 Cr | 2,397.41 Cr | 0.7300 | 204.34 Cr | 54.59 Cr | 781.59 Cr | 712.68 Cr | 54.97 | 1,044.49 Cr | 0.2170 |
| 2021-03-31 | 2,847.02 Cr | 682.39 Cr | 2,164.63 Cr | 0.7603 | 138.91 Cr | 38.40 Cr | 863.72 Cr | 653.87 Cr | 50.06 | 1,024.05 Cr | 0.2297 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 176.24 Cr | 5,014.95 Cr | 1,224.66 Cr | 3,790.2900 Cr | 47.42 Cr | -128.82 Cr | 903.85 Cr | 1,891.77 Cr | 0.00 Cr | 2.00 Cr | 28.95 Cr | 996.1000 Cr |
| 2024-03-31 | 129.49 Cr | 4,638.39 Cr | 1,071.03 Cr | 3,567.3600 Cr | 35.28 Cr | -94.21 Cr | 828.36 Cr | 1,720.98 Cr | 39.32 Cr | 2.34 Cr | 22.74 Cr | 895.7600 Cr |
| 2023-03-31 | 329.83 Cr | 4,679.02 Cr | 1,291.03 Cr | 3,387.9900 Cr | 35.63 Cr | -294.20 Cr | 815.63 Cr | 1,698.16 Cr | 683.93 Cr | 2.67 Cr | 29.00 Cr | 1,139.2800 Cr |
| 2022-03-31 | 206.36 Cr | 4,055.58 Cr | 791.24 Cr | 3,264.3400 Cr | 25.03 Cr | -181.33 Cr | 791.07 Cr | 1,647.42 Cr | 249.35 Cr | 3.00 Cr | 29.42 Cr | 647.3900 Cr |
| 2021-03-31 | 177.51 Cr | 3,778.72 Cr | 783.09 Cr | 2,995.6300 Cr | 31.36 Cr | -146.15 Cr | 766.47 Cr | 1,629.61 Cr | 232.76 Cr | 3.34 Cr | -196.72 Cr | 648.6300 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,157.2300 Cr | -376.5200 Cr | -733.4100 Cr | 839.3100 Cr | 46.0100 Cr | 176.7900 Cr | -317.9200 Cr | 920.3900 Cr | 1.1000 Cr | -349.3700 Cr | -74.5100 Cr |
| 2024-03-31 | 785.0700 Cr | 65.3900 Cr | -1,051.0600 Cr | 632.6600 Cr | -201.4400 Cr | 129.2300 Cr | -152.4100 Cr | 816.1700 Cr | 0.0600 Cr | -642.1700 Cr | -12.3000 Cr |
| 2023-03-31 | 791.7800 Cr | -559.6000 Cr | -107.8700 Cr | 617.2900 Cr | 125.2600 Cr | 330.6700 Cr | -174.4900 Cr | 745.2500 Cr | -0.4900 Cr | -89.6900 Cr | -22.3700 Cr |
| 2022-03-31 | 562.0400 Cr | -74.1000 Cr | -460.0400 Cr | 413.2000 Cr | 28.8800 Cr | 205.4100 Cr | -148.8400 Cr | 909.4800 Cr | 0.2300 Cr | -82.2100 Cr | -25.6600 Cr |
| 2021-03-31 | 576.3100 Cr | -282.3900 Cr | -318.2900 Cr | 404.7000 Cr | -24.7300 Cr | 177.9900 Cr | -171.6100 Cr | 900.1800 Cr | -44.0200 Cr | -82.9000 Cr | -271.4500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,302.65 Cr | 275.88 Cr | 1,026.77 Cr | 0.7882 | 682.58 Cr | 255.34 Cr | 20.44 | 377.68 Cr | 0.1960 |
| 2025-03-31 | 1,170.41 Cr | 283.42 Cr | 886.99 Cr | 0.7578 | 544.21 Cr | 225.26 Cr | 18.04 | 288.34 Cr | 0.1925 |
| 2024-12-31 | 1,146.13 Cr | 257.81 Cr | 888.32 Cr | 0.7751 | 587.18 Cr | 232.88 Cr | 18.60 | 351.27 Cr | 0.2032 |
| 2024-09-30 | 1,186.64 Cr | 261.68 Cr | 924.96 Cr | 0.7795 | 629.61 Cr | 216.48 Cr | 17.27 | 330.65 Cr | 0.1824 |
| 2024-06-30 | 1,144.92 Cr | 585.60 Cr | 559.32 Cr | 0.4885 | 502.65 Cr | 245.77 Cr | 19.54 | 330.35 Cr | 0.2147 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 176.24 Cr | 438.71 Cr | 614.95 Cr | 1,182.74 Cr | 903.85 Cr | 2,843.03 Cr | 1,891.77 Cr | 5,014.95 Cr | 1,224.66 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 741.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,676.95 Cr |
| 2024-09-30 | 63.89 Cr | 676.98 Cr | 741.91 Cr | 1,036.63 Cr | 845.66 Cr | 2,794.78 Cr | 1,786.78 Cr | 4,790.50 Cr | 1,113.55 Cr |
| 2024-06-30 | -459.54 Cr | 919.08 Cr | 459.54 Cr | 0.00 Cr | 0.00 Cr | 459.54 Cr | 0.00 Cr | 0.00 Cr | -3,567.36 Cr |
| 2024-03-31 | 130.77 Cr | 330.05 Cr | 460.82 Cr | 1,246.84 Cr | 828.36 Cr | 2,730.92 Cr | 1,720.98 Cr | 4,638.39 Cr | 1,071.03 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 225.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 232.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 216.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 245.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 202.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 129.23 Cr | 331.29 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-06-22 | June 22, 22 | 3:2 |
| 2015-03-20 | March 20, 15 | 5:2 |
| 2013-09-17 | September 17, 13 | 3:2 |
| 2012-08-09 | August 09, 12 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,609.00 | ₹3,860,441,520,000.00 | ₹1,626,288.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,050.50 | ₹1,606,220,184,500.00 | ₹63,569.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,530.90 | ₹1,195,015,450,500.00 | ₹135,292.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,300.70 | ₹1,082,646,847,453.00 | ₹954,623.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.90 | ₹1,068,589,227,622.00 | ₹92,714.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,036.15 | ₹1,042,605,214,500.00 | ₹296,469.00 |
| Lupin Limited | LUPIN | ₹2,040.60 | ₹932,054,253,000.00 | ₹325,910.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹126,076.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,100.80 | ₹639,346,841,600.00 | ₹870,057.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,100.20 | ₹592,678,540,200.00 | ₹402,431.00 |
| Laurus Labs Limited | LAURUSLABS | ₹893.00 | ₹482,063,725,000.00 | ₹396,445.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹982.00 | ₹375,680,801,856.00 | ₹57,880.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,309.10 | ₹332,123,906,400.00 | ₹70,482.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,555.50 | ₹319,273,948,000.00 | ₹14,183.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,681.60 | ₹263,331,833,600.00 | ₹78,315.00 |
| Piramal Enterprises Limited | PEL | ₹1,132.00 | ₹256,599,496,000.00 | ₹946,023.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,511.10 | ₹245,530,782,791.00 | ₹113,354.00 |
| Eris Lifesciences Limited | ERIS | ₹1,664.90 | ₹226,771,034,300.00 | ₹30,477.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,024.50 | ₹225,612,500,000.00 | ₹7,781.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,790.00 | ₹202,584,121,000.00 | ₹31,902.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹960.00 | ₹188,700,480,000.00 | ₹226,418.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,124.40 | ₹179,095,556,400.00 | ₹61,537.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,266.90 | ₹172,310,922,730.00 | ₹101,864.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹853.50 | ₹152,870,385,000.00 | ₹325,818.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹531.25 | ₹128,904,625,000.00 | ₹689,565.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,267.00 | ₹104,028,439,800.00 | ₹5,131.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹936.70 | ₹84,895,902,062.00 | ₹207,949.00 |
| Strides Pharma Science Limited | STAR | ₹887.40 | ₹81,794,053,980.00 | ₹143,336.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹828.90 | ₹81,058,877,010.00 | ₹111,223.00 |
| FDC Limited | FDC | ₹465.80 | ₹75,836,898,000.00 | ₹37,634.00 |
| Suven Life Sciences Limited | SUVEN | ₹226.01 | ₹49,279,377,929.00 | ₹85,787.00 |
| Innova Captab Limited | INNOVACAP | ₹856.60 | ₹49,018,875,038.00 | ₹10,615.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹513.40 | ₹46,858,018,000.00 | ₹133,136.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.75 | ₹46,650,037,500.00 | ₹131,516.00 |
| Sequent Scientific Limited | SEQUENT | ₹183.98 | ₹46,056,633,300.00 | ₹295,810.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,385.30 | ₹39,450,476,700.00 | ₹8,145.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹365.95 | ₹36,696,734,100.00 | ₹21,786.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹707.00 | ₹35,858,403,700.00 | ₹36,027.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹504.15 | ₹35,495,084,070.00 | ₹8,735.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹118.86 | ₹34,888,619,220.00 | ₹11,214,307.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹676.15 | ₹32,558,650,950.00 | ₹52,292.00 |
| Hikal Limited | HIKAL | ₹260.75 | ₹32,150,735,750.00 | ₹115,051.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.52 | ₹29,326,498,080.00 | ₹1,745,659.00 |
| Indoco Remedies Limited | INDOCO | ₹294.30 | ₹27,148,556,970.00 | ₹140,867.00 |
| Alembic Limited | ALEMBICLTD | ₹104.84 | ₹26,921,024,775.00 | ₹231,892.00 |
Key Executives
President of International Business
Mr. H. Nandkishore Agrawal
Gender: male
Year Born: 1960
Senior Vice President of HR
Mr. Thampy Jacob
Gender: male
Year Born:
Joint MD & Director
Mr. Rajesh Mannalal Agrawal M.B.A
Gender: male
Year Born: 1976
Senior Vice President of Legal, VP of Corporate Affairs, Company Secretary & Compliance Officer
Mr. Gaurang Chinubhai Shah
Gender: male
Year Born:
President of Tech & Operations
Mr. H. Satish Agrawal M Pharm
Gender: male
Year Born: 1963
Deputy General Manager of Sustainability
Mr. Pankaj Barbind
Gender: male
Year Born:
Executive Vice President
Mr. Jagdish Dwarkadas Joshi
Gender: male
Year Born:
MD & Executive Director
Mr. Yogesh Mannalal Agrawal M.B.A
Gender: male
Year Born: 1972
Executive Vice Chairman of the Board
Mr. Madhusudan Bhagwandas Agrawal B.Sc
Gender: male
Year Born: 1955
Chief Financial Officer
Mr. Arvind K. Agrawal B Com, F.C.A, L.L.B
Gender: male
Year Born: 1963
FAQs about Ajanta Pharma Limited
Who is the CEO of the company?
The CEO is Yogesh Mannalal Agrawal.
What is the current market price of the stock?
The current price is ₹2,579.10.
What is the 52-week price range?
The range is ₹2327.3-3428.
What is the market capitalization of the company?
The market capitalization is ₹32,222.24 crores.
What is the dividend yield?
The dividend yield is 1.09%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 34.65.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Ajanta Pharma Limited (ISIN: INE031B01049) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹32,222.24 crores and an average daily volume of 133,680 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹54.